

FIG. 1A




FIG. 1B





FIG. 2A



4/42

FIG. 2B

SEQ ID NO	Name/Component	Sequence
556	Human DLL3 complete ECD	METDTLLWVLLWVPGSTGYVDVDPYAGMLAGVFELQHSFGPGPGAPRSPCSARL PCRLFFRVLKPGISEEAAESPCALGAALSARGPVYTEQGPAPDPLPDGLLQVPRD AWPGTFSEIETWREELGDIQGPWVSLARVAGRRRLAAGGPWARDIQRAGAWELRFSY RARCEPAVGTACTRLCRPSAPSRGPGRLPCAPLEDECEAPLVCRAAGCSPEHGFCEQP GECRCLEGTGPLCTVPVSTSSCLSPRGSSATTGCLVPGPGCDGNPCANGGSCSETPR SFECTCPRGFGLRCEVSGVTCADGPCFNGGLCVGGADPDSAYICHPPGFQGSNCEKRV DRCSLQPCRNGGLCLDLGHALRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHR CSCALGFGGRDCRERADPCAARPCAHHGRCYAHFSGLVACAPGYMGARCEFPVHPDGAS ALPAAPPGLRPGDPQRYLLPPALGLLVAAGVAGAAALLLVHVRRRGHSDAGSRLLAGTPE PSVHALPDALNNLRTQEGSGDGPSSVDWNRPEVDVDPQGIYVISAPSIYAREVATPLEPP LHTGRAGQRQHLLFPYPSSILSVK
557	Human DLL3 DSL-EGF6	METDTLLWVLLWVPGSTGYVDVDPYAGMLGSARCEPPAVGTACTRLCRPSAPSRG PGLRPCAPLEDECEAPLVCRAAGCSPEHGFCEQPGECRCLEGTGWTGPLCTVPVSTSSCLSPR GPSSATTGCLVPGPGCDGNPCANGGSCSETPRSFECTCPRGFGLRCEVSGVTCADGPC FNGGLCVGGADPDSAYICHPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALRCRA GFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDCRERADPCAARPCA HGRCAHFGSLVACAPGYMGARCEFPVHPDGASALPAAPPGLRPGDPQRYLLPPALGLLV AAGVAGAAALLLVHVRRRGHSDAGSRLLAGTPEPSVHALPDALNNLRTQEGSGDGPSSV DWNRPEDVDPQGIYVISAPSIYAREVATPLEPP LHTGRAGQRQHLLFPYPSSILSVK
558	Human DLL3 EGF1 - EGF6	METDTLLWVLLWVPGSTGYVDVDPYAGMLGSAPLVCRAAGCSPEHGFCEQPGECRCLE GWTGPLCTVPVSTSSCLSPRGSSATTGCLVPGPGCDGNPCANGGSCSETPRSFECTCP RGFGLRCEVSGVTCADGPCFNGGLCVGGADPDSAYICHPPGFQGSNCEKRVDRCSLQ PCRNGGLCLDLGHALRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGF GGRDCRERADPCAARPCAHHGRCYAHFSGLVACAPGYMGARCEFPVHPDGASALPAAPP GLRPGDPQRYLLPPALGLLVAAGVAGAAALLLVHVRRRGHSDAGSRLLAGTPEPSVHALP DALNNLRTQEGSGDGPSSVDWNRPEVDVDPQGIYVISAPSIYAREVATPLEPP LHTGRAG QRQHLLFPYPSSILSVK

SUBSTITUTE SHEET (RULE 26)

FIG. 2C

SEQ. ID. NO.	Name/ Component	Sequence
559	Human DLL3 EGF2- EGF6	METDTLLWVLLWVPGSTGYPDYDYGMLSGPGCDGNPCANGSCSETPRSFECT CPRGFYGLRCEVSGVTCADGPGFCNGLCVGGADPDSAYICHCPPGFGQGSNCEKRVDRCSL QPCRNGLCLDLGHALRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCAL GFGGRDCRERADPCAARPCAHGGRCYAHFSGLVCAACAPGYMGARCEFPVHPDGPASALPAA PPGLRPGDPQRYLLPPALGLLVAAGVAGAAALLVHVRRRGHSQDAGSRLLAGTPEPSVHA LPDALNNLRTQEGSGDGPSSVDWNRPEVDVDPQGIYVISAPSIYAREVATPLFPPLHTGR AGQRQHLLFPYPSSILSVK
560	Human DLL3 EGF3- EGF6	METDTLLWVLLWVPGSTGYPDYDYGMLSGSVTCADGPGFCNGLCVGGADPDSAY ICHCPPGFGQGSNCEKRVDRCSLQPCRNGLCLDLGHALRCRAGFAGPRCEHDLDDCAG RACANGGTCVEGGGAHRCSCALFGGGRDCRERADPCAARPCAHGGRCYAHFSGLVCAACAP GYMGARCEFPVHPDGPASALPAAAPPGLRPGDPQRYLLPPALGLLVAAGVAGAAALLVHVR RGHSQDAGSRLLAGTPEPSVHALPDALNNLRTQEGSGDGPSSVDWNRPEVDVDPQGIYVI SAPSIYAREVATPLFPPLHTGRAGQRQHLLFPYPSSILSVK
561	Human DLL3 EGF4- EGF6	METDTLLWVLLWVPGSTGYPDYDYGMLSGRVDRCSLQPCRNGLCLDLGHALRCR CRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALFGGGRDCRERADPCAARPC AHGGRCYAHFSGLVCAACAPGYMGARCEFPVHPDGPASALPAAAPPGLRPGDPQRYLLPPALG LLVAAGVAGAAALLVHVRRRGHSQDAGSRLLAGTPEPSVHALPDALNNLRTQEGSGDGP SSVDWNRPEVDVDPQGIYVISAPSIYAREVATPLFPPLHTGRAGQRQHLLFPYPSSILSVK
562	Human DLL3 EGF5- EGF6	METDTLLWVLLWVPGSTGYPDYDYGMLSGDLDDCAGRACANGGTCVEGGGAHRC CALFGGRDCRERADPCAARPCAHGGRCYAHFSGLVCAACAPGYMGARCEFPVHPDGPASAL PAAAPPGLRPGDPQRYLLPPALGLLVAAGVAGAAALLVHVRRRGHSQDAGSRLLAGTPEPS VHALPDALNNLRTQEGSGDGPSSVDWNRPEVDVDPQGIYVISAPSIYAREVATPLFPPLHTGRAGQRQHLLFPYPSSILSVK
563	Human DLL3 EGF6	METDTLLWVLLWVPGSTGYPDYDYGMLSGRADPCAARPCAHGGRCYAHFSGLVCA CAPGYMGARCEFPVHPDGPASALPAAAPPGLRPGDPQRYLLPPALGLLVAAGVAGAAALLVH VRRRGHSQDAGSRLLAGTPEPSVHALPDALNNLRTQEGSGDGPSSVDWNRPEVDVDPQGI YVISAPSIYAREVATPLFPPLHTGRAGQRQHLLFPYPSSILSVK



6/42
FIG. 2D

CHO-DLL3



Complete ECD

DSL-EGF6



5E12



6D8



26C8



7/42



FIG. 2D
CONTINUED

CHO-DLL3



EGF1-EGF6

EGF2-EGF6



5E12



6D8



26C8



SUBSTITUTE SHEET (RULE 26)

8/42



FIG. 2D
CONTINUED

CHO-DLL3



EGF3-EGF6

EGF4-EGF6



5E12



6D8



26C8



SUBSTITUTE SHEET (RULE 26)

9/42



FIG. 2D
CONTINUED

CHO-DLL3



EGF5-EGF6

EGF6



5E12



6D8



26C8



SUBSTITUTE SHEET (RULE 26)

FIG. 3A

DLL3 CAR domain structure




FIG. 3B




FIG. 3C

Clone	Transduction efficiency (Donor 116)	Transduction efficiency (Donor 117)	Transduction efficiency (Donor 116)	Transduction efficiency (Donor 419)
2A6.C5	37.2 %	37.7 %	31.0 %	22.7 %
2D3	46.1 %	47.4 %	66.9 %	49.1 %
5A2	49.1 %	47.4 %	58.3 %	46.4 %
5C1.A4	0.31 %	NA	16.3 %	12.2 %
5E12	53.8 %	49.1 %	67.5 %	49.4 %
6D8	32.4 %	34.8 %	48.9 %	35.2 %
7F9	42.2 %	37.4 %	5.81 %	2.70 %
8E11	39.1 %	41.4 %	<0.1 %	<0.1 %
9D3	52.4 %	50.8 %	<0.1 %	<0.1 %
9F7	0.24 %	0.15 %	15.2 %	4.08 %
26C8	48.9 %	46.9 %	52.4 %	40.2 %
			42.7 %	27.1 %
			68.6 %	43.3 %
2C3				
2G1				
3E4				
3F2				
4F9				
4G9				
6H1				
6H5				
10D1				
11F6				
11H7				
16H7				
17A2				


FIG. 3D

Clone	Transduction efficiency (Donor 503)	Transduction efficiency (Donor 772)	Transduction efficiency (Donor 419)	Transduction efficiency (Donor 503)
4H5	<0.1%	<0.1%		
6F8	59.4%	26.7%		
3G6 - L1	35%	14.2%		
3G6 - L2	33.5%	16.9%		
4C6	56.9%	25.2%		
3B9	<0.1%	<0.1%		
4E6	37.8%	24.8%		
3F9-L	19.5%	13.8%		
4H8	39.3%	27.2%		
3E10	<0.1%	0.43%		
3C3	<0.1%	0.14%		
11F4	<0.1%	0.43%		
9H12-K	41.4%	35.6%		
10E12	<0.1%	0.98%		
10G1-K	53.7%	33.7%		
11A3	42.1%	20%		

Clone	Transduction efficiency (Donor 419)	Transduction efficiency (Donor 503)
3B11	57.3%	65.8%
4E1	2.35%	3.18%
5G2	36.7%	42.8%
2404.6H1	6.01%	6.41%
2A8-K	<0.1%	<0.1%
3B1	6.15%	7.95%
9B5	<0.1%	<0.1%
11E4	54.8%	62.8%
2404.8E11	NA	58.9%
11A5	NA	0.11%
10A2	58.5%	67.6%
11A8	33.4%	45.1%

NA, not available

FIG. 4A



15/42

FIG. 4B




FIG. 4C




FIG. 5




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7A




FIG. 7B




FIG. 8




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13A





FIG. 13B







FIG. 14C

Human CD3 Staining Score (Day 49)

Group	Animal	Brain	Pituitary
Non-transduced T cells	#1	1	1
	#2	1	1
	#3	1	1
	#4	2	3
DLL3 CAR T	#5	1	3
	#6	1	3

Staining score:
0 = No staining
1 = Sparse-to-moderately low staining
2 = Moderate-to-moderately high staining
3 = Abundant staining

FIG. 14D


Histopathology Analysis (Day 49)

Group	Animal	Brain	Pituitary
Non-transduced T cells	#1	NSML	NSML
	#2	NSML	NSML
	#3	NSML	NSML
	#4	NSML	Infiltrate, mixed cell (severity*=3)
DLL3 CAR T	#5	NSML	Infiltrate, mononuclear cell(severity=2)
	#6	NSML	Infiltrate, mononuclear cell(severity=2)

NSML=No Significant Microscopic Lesions
*Severity: 1=Minimal; 2=Mild; 3=Moderate

35/42

FIG. 14E






FIG. 15A




FIG. 15B




FIG. 15C

Human CD45 Staining Score (Day 36 or 38)

Group	Animal	Brain	Pituitary	Spleen
Non-transduced T cells	#1	1	1	3
	#2	1	1	3
	#3	1	1	3
	#4	1	1	3
	#5	1	1	3
DLL3 CAR T	#6	1	2	3
	#7	1/2	1/2	3
	#8	1	1/2	3
	#9	1	1/2	3
	#10	1	1/2	2
EGFRvIII CAR T	#11	1	1	2
	#12	1	1	3
	#13	1	1	2
	#14	1	1	3
	#15	1	1	3

hCD45 Staining score:
0 = No staining
1 = Rare/Sparse staining
2 = Sparse-to-moderately low staining
3 = Moderate-to-moderately high staining
4 = Abundant staining

FIG. 15D

Histopathology Analysis (Day 36 or 38)

Group	Animal	Brain	Pituitary
Non-transduced T cells	#1	NSML	NSML
	#2	Tumor present	NSML
	#3	Tumor present	NSML
	#4	Tumor present	NSML
	#5	Tumor present	NSML
DLL3 CAR T	#6	Tumor present	Infiltrate, mononuclear cell (severity=2)
	#7	Tumor present	Infiltrate, mononuclear cell (severity=2)
	#8	Tumor present	Infiltrate, mononuclear cell (severity=1)
	#9	NSML	Infiltrate, mononuclear cell (severity=2)
	#10	NSML	Infiltrate, mononuclear cell (severity=2)
EGFRvIII CAR T	#11	NSML	NSML
	#12	NSML	NSML
	#13	NSML	NSML
	#14	NSML	NSML
	#15	NSML	NSML

NSML=No Significant Microscopic Lesions
**Severity: 1=Minimal; 2=Mild; 3=Moderate

FIG. 16A




FIG. 16B




FIG. 16C

